The investigators have previously demonstrated that the administration of insulin in the form of an infusion with additional sugar and potassium may improve cardiovascular performance and reduce biochemical evidence of heart muscle injury in non-diabetic patients undergoing coronary artery surgery. The investigators now seek to demonstrate that similar benefits can be achieved in diabetic patients by administering insulin to maintain as near absolutely normal sugar levels as possible.

The difference in the mean left ventricular end-systolic volume index (LVESVI) after CABG and the amount of new permanent injury detected in the late CMRI study [ Time Frame: 3 months post CABG ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Glycaemic control will be assessed 2 hours pre-operatively and 72 hours post-operatively. Measurement timings will be standardized allowing comparison of glycaemic control during different time-periods. [ Time Frame: 72 hours post CABG ] [ Designated as safety issue: No ]

Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution

No Intervention: 2

Normal departmental practice using dextrose insulin infusion

Eligibility

Ages Eligible for Study:

18 Years to 80 Years (Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Type II diabetes mellitus patients (as defined by WHO)

Diet, oral hypoglycaemic or insulin therapy

Undergoing elective and urgent coronary artery bypass surgery

Exclusion Criteria:

Non-diabetics

Emergency and redo CABG

< 18 years

Pregnancy

Dialysis-dependence

History of CVA/TIA < 6 months

Heart valve disease requiring surgery

STEMI < 3 months

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00899483